Peptides for energy and mitochondrial health
Almost every cell in your body runs on fuel made by mitochondria, and how well they work shapes how you feel day to day. This topic covers peptides for energy and the molecules behind it — NAD, which cells use to move energy around, and mitochondrial peptides like MOTS-c and SS-31.
The articles explain the science the way you'd want a friend to: what these compounds are, what studies show, and what's still unproven. All are prescription-only through a licensed provider.
38 articles on this topic
-
TAZPOWER Trial: What the Results Actually Show
TAZPOWER missed its main walking and fatigue goals against placebo. Longer follow-up reported gains, with enough uncertainty to require another trial.
-
MOTS-c Anti Aging: Human Benefits Remain Unproven
MOTS-c has not been shown to slow aging in people. Mouse findings and human blood measurements answer narrower questions about aging.
-
MMPOWER-3 Trial: Walking and Fatigue Goals Not Met
After 24 weeks, elamipretide did not beat placebo on walking distance or fatigue. A later genetic subgroup finding led to another trial, not a new verdict.
-
Who Discovered NAD? The History Behind NAD+
Harden and Young found NAD's activity in yeast experiments, with a detailed paper in 1906. The vitamin, Nobel and longevity chapters came later.
-
Should I Take NAD+? A Provider's Decision Path
The answer starts with your goal and what is causing the tiredness. Oral supplement findings don't establish what NAD+ injections would do for you.
-
Forzinity Prescribing Information: Plain English
Forzinity’s label covers Barth syndrome, a daily injection, and specific safety limits. Here’s what each section means.
-
SS-31 News: October 2026 Update
Forzinity's follow-up trial is underway. Fresh mouse and cell studies add research questions, while the label remains limited to Barth syndrome.
-
NAD+ Myths: 7 Claims Checked Against the Evidence
Some swallowed supplements raise blood NAD+. That doesn't show injections make people younger or that a drip into a vein works better than a shot.
-
Should I Take MOTS-c? Start With These Questions
MOTS-c isn't an established treatment for weight loss or tiredness. A provider weighs the thin human evidence, your medicines and sports rules before deciding whether it fits.
-
NAD+ News Update: September 2026
Supplements kept raising blood NAD+ this quarter without moving memory, fatigue or sleep scores, and NAD+'s regulatory status stayed where it was. Here is every dated change, June through September.
-
MOTS-c News Update: September 2026
July's FDA advisory vote was the quarter's headline, but no rule has followed it. Here is what changed for MOTS-c from June to September, and what did not.
-
MOTS-c Exercise Claims: What the Studies Show
MOTS-c is called an exercise mimetic because exercise raises it in people and administered MOTS-c changed running performance in mice. No published human trial shows that taking it improves a workout.
-
Who Discovered MOTS-c? The 2015 USC Discovery
Changhan Lee, Pinchas Cohen, and their colleagues reported MOTS-c in 2015. Its history runs from an overlooked genetic sequence to human observations and an ongoing question about treatment.
-
Forzinity Approval: One Year Later
On September 19, 2025, Forzinity became the first treatment for Barth syndrome through accelerated approval. A year later, that narrow decision still rests on a required confirmatory trial.
-
MOTS-c and Retatrutide: No Evidence for a Stack
No published study has tested MOTS-c and retatrutide together. Retatrutide cannot be compounded for patient care, while MOTS-c is a separate prescription discussion with much thinner human evidence.
-
MOTS-c for Weight Loss: Human Evidence Is Thin
Mouse studies are interesting, but no completed randomized trial shows that MOTS-c causes weight loss in people. Human studies so far mostly measure the peptide already in the body.
-
MOTS-c Tablets: No Human Evidence Supports Them
MOTS-c tablets have no published human absorption data. The studies behind the peptide used injected animals or measured the MOTS-c people made themselves.
-
MOTS-c vs Tesamorelin: Not a Fat-Loss Contest
MOTS-c and tesamorelin work through different systems, and their evidence is not comparable. Tesamorelin has large late-stage trials for one narrow HIV-related condition; MOTS-c does not yet have completed human treatment results.
-
SS-31 Side Effects: What the Trials Found
SS-31 most often caused redness, itching, pain, or swelling where it was injected. Most reactions in trials were mild to moderate, but the label also warns about allergic reactions that can become serious.
-
MOTS-c Before and After: What Research Shows
MOTS-c before and after photos are not clinical evidence. Human research has measured exercise and metabolic markers, but no completed study has published visible results from giving native MOTS-c—the exact peptide, not an altered analogue—to people.
Page 1 of 2 · 38 articles